Abbvie Biotherapeutics Inc.

Abbott Biotherapeutics Corp.

Agensys, Inc.

Facet Biotech Corporation

Gao Liu

J Yun Tso

Nicholas F Landolfi

Marna Williams

David Powers

Josh Snyder

Faisal Hayat Malik

Nandini Rudra-Ganguly

Christine Lowe

Sung Ju Moon

Hector Avina

Cyrus Virata

Linnette Capo

Yun J Tso

Nicolas F Landolfi

David B Powers

Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Antibody drug conjugates (ADC) that bind to FLT3 proteins

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Therapeutic use of anti-CS1 antibodies

Growing community of inventors

Mountain View, CA, United States of America

Gao Liu